TRAF3 and neoplasm: In light of these observations, the present study sought to evaluate the therapeutic potential of PKCδ activation in TRAF3-/- tumor B cells using two pharmacological activators of PKCδ, N-Benzyladriamycin-14-valerate (AD 198) and ingenol-3-angelate (PEP005) [20-25].